(±)-2,5-二甲氧基-4-溴苯丙胺氢溴酸盐 | 53581-53-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (&plusmn)-2,5-二甲氧基-4-溴苯丙胺氢溴酸盐
• 中文别名: (+/-)-2,5-二甲氧基-4-溴-安非他命氢溴酸盐
• 英文名称: 1-(2,4-dimethoxy-4-bromophenyl)-2-aminopropane hydrobromide
• 英文别名: 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane hydrobromide；(+/-)-1-(2,5-dimethoxy-4-bromophenyl)propan-2-amine hydrobromide；1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine;hydron;bromide
• CAS: 53581-53-6
• 化学式: BrH*C₁₁H₁₆BrNO₂
• 分子量: 355.069
• InChiKey: KOUBEZAODVTFTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.26
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (±)-2,5-二甲氧基-4-溴苯丙胺氢溴酸盐 在 硼烷 、 三乙胺 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 生成 Benzyl-[2-(4-bromo-2,5-dimethoxy-phenyl)-1-methyl-ethyl]-amine
  参考文献：
  名称：

  Influence of Amine Substituents on 5-HT2A versus 5-HT2C Binding of Phenylalkyl- and Indolylalkylamines

  摘要：

  The effect of 15 different amine substituents on 5-HT2A and 5-HT2C serotonin receptor binding was investigated for two series of compounds (i.e., phenylalkylamine and indolylalkylamine derivatives). In general, amine substitution decreases receptor affinity; however, N-(4-bromobenzyl) substitution results in compounds that bind at 5-HT2A receptors with high affinity (K-i < 1 nM) and with >100-fold selectivity. Although parallel structural modifications in the two series result in parallel shifts in 5-HT2C binding, these same modifications alter 5-HT2A binding in a less consistent manner.

  DOI：

  10.1021/jm00039a004

文献信息

• Dopamine analog amide
  申请人：——

  公开号：US20010056116A1

  公开（公告）日：2001-12-27

  The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

  该发明涉及使用脂肪酸载体和神经活性药物形成前药。该前药在胃和血液流动环境中稳定，并可通过口服递送。该前药容易穿过血脑屏障。一旦进入中枢神经系统，前药被水解成脂肪酸载体和药物以释放药物。在首选实施方式中，载体是4,7,10,13,16,19二十二碳六烯酸，药物是多巴胺。两者都是中枢神经系统的正常成分。药物和载体之间的共价键通常是酰胺键，这种键可以在胃的条件下存活。因此，前药可以被摄入，并且不会在胃中完全水解成载体分子和药物分子。
• Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction
  申请人：Wyeth

  公开号：US20040063721A1

  公开（公告）日：2004-04-01

  The present invention relates to a method for treating thermoregulatory disorders by administering compounds and compositions of compounds which by modulating 5HT levels activate the 5HT 2a receptor. The invention also relates to therapy using 5HT 1a antagonists and SRIs in combination and pharmaceutical compositions and products containing it. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

  本发明涉及一种通过施用化合物和化合物组合物治疗体温调节失调的方法，这些化合物和化合物组合物通过调节 5HT 水平激活 5HT 2a 受体。本发明还涉及使用 5HT 1a 拮抗剂和 SRIs 结合使用的治疗方法，以及含有这种药物的药物组合物和产品。需要强调的是，提供本摘要是为了符合要求摘要能使检索者或其他读者迅速确定技术公开主题的规则。提交本摘要的前提是，本摘要不用于解释或限制权利要求的范围或含义。
• AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
  申请人：Wyeth

  公开号：EP1534258A2

  公开（公告）日：2005-06-01
• US5994392A
  申请人：——

  公开号：US5994392A

  公开（公告）日：1999-11-30
• US6107499A
  申请人：——

  公开号：US6107499A

  公开（公告）日：2000-08-22